National health experts are closely watching the potential cancer‑fighting benefits of GLP‑1 receptor agonists, the same class of drugs that have transformed obesity and diabetes treatment. The American Association for Cancer Research’s 2026 Cancer Progress Report underscored obesity as a leading cause of many cancers and noted that early data suggest GLP‑1 medications could help reverse that risk.
What the research shows
Dr. Sai Yendamuri, a thoracic surgeon at Roswell Park Comprehensive Cancer Center in Buffalo, New York, explained that obesity ranks second only to smoking as a driver of cancer. “If obesity is related to cancer – both in terms of causing it and increasing its progression – the logical question is whether a drug that decreases obesity would have an impact,” he told Fox News Digital.
Retrospective analyses of patients who underwent metabolic surgery have already demonstrated lower cancer rates after significant weight loss. Building on that, researchers have compared outcomes for patients taking GLP‑1 receptor agonists with those who do not. Many of these studies found a reduced cancer risk and higher survival among GLP‑1 users.
Mixed findings and ongoing questions
While the majority of investigations point toward a protective effect, some studies have not found a clear link, and a few even reported a higher incidence of specific cancers, such as thyroid cancer. Dr. Yendamuri attributed these discrepancies to the retrospective nature of the data, which can be influenced by numerous variables.
He emphasized that obesity’s definition matters. Traditional reliance on body‑mass index (BMI) is giving way to more precise measurements of body‑fat composition, which may sharpen future research conclusions.
Potential mechanisms
Laboratory work suggests GLP‑1 drugs may modestly affect cancer cells directly, but their primary benefit appears to stem from altering the body’s immune response. “What we think is happening is that it changes the body’s immune response to cancer cells, thereby improving its ability to fight cancer,” Dr. Yendamuri said.
The immune‑mediated effect may vary by cancer type. For cancers where the immune system plays a crucial role—such as melanoma—the impact could be especially pronounced.
Clinical observations
In surgical settings, Dr. Yendamuri noted that lung‑cancer patients on GLP‑1 therapy experienced lower recurrence rates after resection. Similarly, advanced‑stage cancer patients receiving immunotherapy alongside GLP‑1 drugs showed reduced recurrence.
He cautioned that not every patient on a GLP‑1 agent loses a substantial amount of weight. Future trials will need to determine whether the cancer‑protective benefit is tied to weight loss itself or to the medication’s other effects.
Looking ahead
Dr. Yendamuri remains hopeful that, with rigorous randomized clinical trials, GLP‑1 medications could become a standard component of cancer prevention strategies. “More and more, we are realizing that lifestyle modifications – exercise, decreasing weight, and now GLP‑1 receptor agonists – will all have a role in both enhancing the treatment of cancer as well as preventing second cancers,” he said.
He also stressed the importance of continued federal funding for the National Cancer Institute, which supports the research needed to clarify these promising signals.
Original reporting: Fox News (HLL/CB) — read the source article.
